Ask AI
ProCE Banner Series

Immunotherapy and Beyond in Metastatic NSCLC: Where Are We Now and What’s Next?

Join us online for this interactive breakfast roundtable webinar featuring Christine Bestvina, MD, and Elaine Shum, MD, live from the IASLC 2023 North America Conference on Lung Cancer discussing immunotherapy combinations as management for patients with metastatic NSCLC. Register now!

  AMA
Who Should Attend

This program is intended for medical oncologists and other healthcare professionals who care for patients with lung cancer.

All Events

Immunotherapy and Beyond in Metastatic NSCLC: Where Are We Now and What’s Next?

Past Events

December

01

2023

6:00 AM - 7:00 AM Central Time (CT)

Virtual

Topics

  • Welcome and Introduction
  • Current Immunotherapy Landscape and Practice-Changing Clinical Trials
    • Metastatic NSCLC (ICI-naive patients)
    • Metastatic NSCLC (previous ICI exposure)
  • Clinical Factors Influencing Response to ICIs
    • Genomic predictors of lack of benefit with ICI-based therapy
  • When to Use ICI Monotherapy and When to Combine With Chemotherapy, Radiation, or Other Therapies in the First-line Setting
  • Distinguishing irAEs From Chemotherapy and Targeted Therapy AEs With Combination Therapy and Appropriate Management
    • Equipping your team to promote health equity
  • Final Panel Discussion and Audience Question and Answer Session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment with immunotherapy for patients with metastatic NSCLC.

Target Audience
This program is intended for medical oncologists and other healthcare professionals who care for patients with lung cancer. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Select optimal immunotherapy-based regimens for patients with metastatic NSCLC
  • Assess how emerging novel treatments and immunotherapy agents for metastatic NSCLC might be integrated into current treatment paradigms
  • Develop multidisciplinary team strategies to effectively mitigate and manage adverse events associated with immunotherapies in patients with metastatic NSCLC while maintaining the most effective treatment regimens
  • Foster health equity via identification of diverse patient populations suitable for enrollment in ongoing clinical trials and treatment strategies employing immunotherapy for patients with metastatic NSCLC

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by an educational grant from AstraZeneca.

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191